908 Devices Inc.

MASS

$9.97

-0.70%

2026-09-04 12:27:35 EDT-$0.07

Healthcare

Medical - Specialties

NASDAQ

Negociación activa

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. ...

Análisis fundamental de MASS

Fortalezas clave

Proprietary HPMS (High-Pressure Mass Spectrometry) technology provides a competitive moat.

Strong product portfolio with handheld devices (MX908, XplorIR, ThreatID) designed for mission-critical applications.

Factores de riesgo

Persistent unprofitability with negative net margin (-56.7%) and operating margin (-46%).

High valuation multiples (P/S 6.75, EV/Sales 6.21) leave little room for error.

Rentabilidad

Margen neto-56.68%

Margen operativo-46.01%

Valoración

PER-10.80x

Ratio corriente2.67

Eficiencia

ROE-25.50%

ROA-17.46%

Análisis Fundamental de MASS

908 Devices Inc. is a niche player in the handheld mass spectrometry and FTIR devices market, targeting public safety, defense, and industrial applications. The company's proprietary HPMS technology provides a competitive edge, enabling rapid on-site chemical identification. Financially, MASS is in a growth phase but remains unprofitable. The latest TTM figures show gross margin at 49.8%, but operating margin is deeply negative at -46%, with a net margin of -56.7%. The company has a strong balance sheet with a current ratio of 2.67 and a quick ratio of 2.38, indicating ample liquidity. Debt levels are low, with debt-to-equity of 0.239 and minimal long-term debt. However, the company's revenue growth has been sluggish, with TTM revenue per share of $1.61, and the stock trades at a high price-to-sales ratio of 6.75, reflecting elevated expectations. The recent price surge (+13.75%) suggests positive sentiment, likely due to preliminary Q4 results indicating stronger revenue and improved outlook. The company continues to invest heavily in R&D (21.6% of revenue), which is essential for product innovation but weighs on profitability. With an EV/Sales of 6.21 and negative EBITDA, the valuation is challenging. However, the company has a cash position of $4.36 per share, providing a runway for operations. Analyst consensus is mixed, with some seeing potential in the company's niche and growth opportunities, while others cite profitability concerns. Long-term, if MASS can scale revenue and achieve operating leverage, it could become profitable, but near-term risks include continued losses and market acceptance.

Fortalezas clave de MASS

Proprietary HPMS (High-Pressure Mass Spectrometry) technology provides a competitive moat.
Strong product portfolio with handheld devices (MX908, XplorIR, ThreatID) designed for mission-critical applications.
Robust balance sheet with a current ratio of 2.67 and low debt levels.
High gross margin of 49.8%, indicating potential for profitability as revenue scales.
Significant R&D investment (21.6% of revenue) drives innovation and future product enhancements.
Diversified revenue streams across public safety, defense, and industrial sectors.
Low beta (0.633) suggests lower volatility compared to the broader market.

Factores de riesgo de MASS

Persistent unprofitability with negative net margin (-56.7%) and operating margin (-46%).
High valuation multiples (P/S 6.75, EV/Sales 6.21) leave little room for error.
Dependence on government and public safety budgets, which may be subject to spending cuts.
Competitive pressure from larger, well-established analytical instrument companies (e.g., Thermo Fisher, Bruker).
Limited revenue growth; TTM revenue per share is only $1.61, and the company is still scaling.
Negative cash flow from operations (operating cash flow ratio of 0.025) and minimal free cash flow.
Supply chain and regulatory risks inherent in the medical and safety device industry.

Capitalización vs ingresos y beneficios

Beneficios

n/a

Ingresos

n/a

Capitalización bursátil

$411.91M

-10.8x

Ratio P/E

6.8x

Ratio P/S

Beneficios e ingresos

Último informen/a

Beneficio por acción (EPS)n/a

Margen bruto49.79%

Margen neto-56.68%

Ratio deuda/capital0.03

Puente de rentabilidad (actual vs interanual)

Muestra cómo cambiaron el margen bruto, operativo y neto frente al año anterior.

Historial de ingresos / beneficio neto / FCF (USD B)

Señales de crecimiento de MASS

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Ingresos	—	—	—	—	Plano
EPS diluido	—	—	—	—	Plano
Flujo de caja libre	—	—	—	—	Plano

Rentabilidad de MASS

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Margen neto	—	-74.00%	—	—	Plano
Margen operativo	—	-79.69%	—	—	Plano
ROE	—	—	—	—	Plano

Salud financiera de MASS

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
Ratio corriente	—	2.671	—	—	Plano
Ratio rápido	—	2.380	—	—	Plano
Deuda / capital	—	0.034	—	—	Plano

Valoración de MASS

Métrica	Actual	Anterior	InteranualCambio interanual: trimestre actual frente al mismo trimestre del año pasado.	TrimestralCambio trimestral: trimestre actual frente al trimestre anterior inmediato.	Señal
P/E	—	-6.80x	—	—	Plano
P/B	—	2.59x	—	—	Plano

Supply Chain de MASS

RELATIONS

Upstream

Micronit Microtechnologies BVMilliporeSigma (Merck KGaA)ETR:MRKSpecialty Electronics & PCB Manufacturers (Multiple Unnamed Suppliers)Specialty Glass & Materials Suppliers (Unnamed)Proprietary Vacuum Pump & Ion Trap Component Manufacturers (In-House Assembly Outsourced Sub-components)General Electric (GE HealthCare / legacy GE components supply chain)NASDAQ:GEHC

Downstream

United States Department of Defense (US Army, US Air Force)United States Department of Homeland Security (Customs & Border Protection, ICE)Drug Enforcement Administration (DEA)NATO Support and Procurement Agency (NSPA)U.S. State & Local Law Enforcement AgenciesRepligen CorporationNASDAQ:RGEN Thermo Fisher Scientific Inc.NYSE:TMOUnnamed Large Analytical Instrumentation CompanySouthern Scientific LtdSartorius Korea Biotech Co. Ltd. (subsidiary of Sartorius AG)ETR:SRT3Rhenium LtdNoster Tec SRLIner-Tech

Proxies

Repligen CorporationNASDAQ:RGEN Thermo Fisher Scientific Inc.NYSE:TMOMerck KGaA (MilliporeSigma)ETR:MRKSartorius AGETR:SRT3

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal